Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals

Devin M. West, Lindsay M. McCauley, Jeffrey S. Sorensen, Al R. Jephson, Nathan C. Dean
ERJ Open Research 2016 2: 00011-2016; DOI: 10.1183/23120541.00011-2016
Devin M. West
1Dept of Medicine, Intermountain Medical Centre, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay M. McCauley
2Division of Pulmonary and Critical Care Medicine, Intermountain Medical Centre, Salt Lake City, UT, USA
3Division of Respiratory, Critical Care, and Occupational Medicine, Dept of Internal Medicine, University of Utah, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Sorensen
2Division of Pulmonary and Critical Care Medicine, Intermountain Medical Centre, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Al R. Jephson
2Division of Pulmonary and Critical Care Medicine, Intermountain Medical Centre, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan C. Dean
2Division of Pulmonary and Critical Care Medicine, Intermountain Medical Centre, Salt Lake City, UT, USA
3Division of Respiratory, Critical Care, and Occupational Medicine, Dept of Internal Medicine, University of Utah, Salt Lake City, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Nathan.Dean@imail.org
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The pneumocococcal urine antigen test increases specific microbiological diagnosis over conventional culture methods in pneumonia patients. Data are limited regarding its yield and effect on antibiotic prescribing among patients with community-onset pneumonia in clinical practice.

We performed a secondary analysis of 2837 emergency department patients admitted to seven Utah hospitals over 2 years with international diagnostic codes version 9 codes and radiographic evidence of pneumonia.

Mean age was 64.2 years, 47.2% were male and all-cause 30-day mortality was 9.6%. Urinary antigen testing was performed in 1110 (39%) patients yielding 134 (12%) positives. Intensive care unit patients were more likely to undergo testing, and have a positive result (15% versus 8.8% for ward patients; p<0.01). Patients with risk factors for healthcare-associated pneumonia had fewer urinary antigen tests performed, but 8.4% were positive. Physicians changed to targeted antibiotic therapy in 20 (15%) patients, de-escalated antibiotic therapy in 76 patients (57%). In 38 (28%) patients, antibiotics were not changed. Only one patient changed to targeted therapy suffered clinical relapse. Length of stay and mortality were lower in patients receiving targeted therapy.

Pneumococcal urinary antigen testing is an inexpensive, noninvasive test that favourably influenced antibiotic prescribing in a “real world”, multi-hospital observational study.

Abstract

Pneumococcal urinary antigen test in pneumonia http://ow.ly/sm8R303lOe0

Introduction

Streptococcus pneumoniae is the most commonly identified bacteria causing community-acquired pneumonia [1]. The pneumocococcal urine antigen test (UAT) is an assay commonly used to identify pneumococcal antigens excreted into the urine to increase the rate of specific microbiological diagnosis over conventional culture methods [2, 3]. Positive tests have been associated with more severe disease including admission to the intensive care unit (ICU), in-hospital treatment failure and increased 30-day mortality [4]. The BinaxNOW (Alere, Waltham, MA, USA) is the most common pneumocococcal UAT utilised in the USA and, in a recent meta-analysis, it had a pooled sensitivity and specificity of 74.0% (95% CI 66.6–82.3%) and 97.2% (95% CI 92.5–99.8%), respectively [5]. Data are limited regarding the test's use and effect on antibiotic prescribing in clinical practice settings.

The Infectious Diseases Society of America/American Thoracic Society 2007 community-acquired pneumonia guidelines state that more research is needed regarding whether or not the pneumocococcal UAT allows for narrowing of empiric antibiotic therapy to a single, specific antibiotic [1]. Two randomised, controlled trials examined the impact of pneumococcal UAT testing on therapy choice with one of the studies showing increased rate of relapse among those treated with Streptococcus pneumoniae-targeted therapy after positive UAT [6, 7]. There were otherwise no differences in clinical outcomes between the study groups. van der Eerden et al. [8] demonstrated fewer side effects in a randomised controlled trial of pathogen directed therapy versus empirical, broad-spectrum antibiotics. There are little existing data regarding pneumococcal UAT-based antibiotic therapy alteration. The British Thoracic Society 2009 pneumonia guidelines recommend that the pneumocococcal UAT only be performed on patients with moderate or high-severity pneumonia [9].

We hypothesised that the pneumocococcal UAT is often misapplied in clinical practice, becoming a needless expense without much added clinical benefit. We also hypothesised that its results are often ignored, with clinicians giving more heed to blood or sputum cultures. We therefore investigated the yield and impact of the pneumocococcal UAT among emergency department patients with community-onset pneumonia admitted to seven Utah hospitals.

Methods

We performed a secondary analysis of electronic medical data from 2837 patients aged 18 years and older admitted with international diagnostic codes version 9 (ICD-9) and radiographic evidence of pneumonia evaluated in the emergency departments of seven Intermountain Healthcare hospitals [10]. All patients were enrolled during two study periods: December 2009–November 2010 and December 2011–November 2012. The gap year stems from the original purpose of this database to study impact of an electronic clinical decision support tool; additional details have been previously published [10]. Cultures of blood and sputum, ordering of urinary antigens, and viral PCR panels were at the discretion of clinicians as part of usual care. Standing orders instructed respiratory therapists to obtain tracheal aspirate for culture in patients for respiratory failure; methods for reporting causative pathogens have also been previously described [11].

These seven adult hospitals serve approximately half of the 2 million people residing in Northern Utah's urban corridor. Intermountain Medical Center is the largest of these hospitals, with 86 400 emergency department visits during 2012, and is affiliated with University of Utah residency programmes including emergency medicine and internal medicine. Three of the hospitals are smaller community hospitals with fewer than 30 000 emergency department visits annually. Standardised admission order sets for pneumonia patients included an order for UAT, pre-selected for ICU patients but requiring a check box for ward-admitted patients.

Two study authors (D.M. West and L.M. McCauley) manually reviewed medical records of patients with a positive pneumocococcal UAT (obtained at any time during the hospital admission) to determine the test's impact on antibiotic treatment. These authors collaborated extensively to promote standardisation and avoid duplication and misclassification of data and counselled with the senior author (N.C. Dean) as needed for guidance. We classified change in antibiotic therapy as targeted (single penicillin-class antibiotic such as penicillin, ampicillin, or amoxicillin), de-escalated (decreased number of antibiotics and/or spectrum of antimicrobial activity) or unchanged (includes patients where additional antibiotics were administered). We also analysed the database for clinical factors predicting UAT positivity.

The study was approved by the Intermountain Healthcare Institutional Review Board and the Intermountain Privacy Board, and authorised by the Utah Population Database. Individual patient consent was not required.

Statistics

Pearson's Chi-squared test was used to compare proportions and rates, and Wilcoxon rank sum test was used to compare continuous, non-Gaussian distributions. Multivariable logistic regression was used to measure the effect of predictors on binary outcomes, with the Hosmer–Lemeshow goodness-of-fit test for model calibration.

Results

Of 2837 emergency department patients admitted to the hospital with pneumonia, 1110 (39%) underwent pneumocococcal UAT yielding 134 positives (12%) (figure 1). Patients with healthcare-associated pneumonia (HCAP) [12] (n=541) were less likely than those with community-acquired pneumonia (n=2296) to have UAT performed (33.1 versus 40.5%, respectively; p=0.002) and less likely to be positive (8.4 versus 12.8%, respectively; p=0.13). Of the 2837 patients, mean age was 64.2 years, 47.2% were male and 41.7% were admitted to the intensive care unit within 72 h of their emergency department visit. All-cause 30-day mortality was 9.6%. Figure 2 shows the percentage of different pathogens identified by a combination of blood, sputum, tracheal aspirates, viral PCR and UAT for pneumococcus and legionella. Of 2837 patients, 6% were identified with pneumococcal pneumonia.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Study population: seven emergency departments. UAT: urine antigen test; CAP: community-acquired pneumonia; HCAP: healthcare-associated pneumonia; ICU: intensive care unit.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella, Peptostreptococcus and other Streptococcal species.

In a multivariable logistic regression measuring the likelihood of obtaining a pneumocococcal UAT, those younger in age, those with lower arterial oxygen saturation/inspiratory oxygen fraction ratios, and those admitted to the intensive care unit were more likely to undergo UAT (tables 1 and 2). Most (94%) UAT were performed within 24 h of hospital admission.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical parameters for community-acquired pneumonia patients stratified by whether a urine antigen test was obtained.

Patients admitted to the intensive care unit had a greater proportion of positive UAT compared with those admitted to the hospital ward (15 versus 8.8%, respectively; p<0.01). On multivariable logistic regression, only those admitted to the intensive care unit were more likely to test positive (OR 1.84, 95% CI 1.24–2.74; p=0.004) (table 3).

View this table:
  • View inline
  • View popup
TABLE 2

Clinical parameters for healthcare-associated pneumonia patients, stratified by whether a urine antigen test was obtained

View this table:
  • View inline
  • View popup
TABLE 3

Clinical parameters for patients with a positive UAT, stratified by antibiotic therapy

In response to positive pneumococcal UAT, physicians changed to targeted antibiotic therapy in 15% of cases (n=20) with only one case of clinical relapse (5%) (figure 3). Reviewing that one case, follow-up cultures were negative and the relapse was attributed by treating clinicians to fluid overload. Of the 20 patients receiving targeted therapy, 19 had blood cultures obtained with only two positive for Streptococcus pneumoniae. We noted de-escalation of therapy in 76 (57%) patients, the most common patterns being de-escalation from empiric therapy of vancomycin and pipercillin–tazobactam to ceftriaxone and azithromycin or simply discontinuing vancomycin. De-escalation occurred within 24 h of the UAT result in 60 (62.5%) patients, and was not associated with relapse. We noted no change in antibiotic therapy in 38 (28%) patients, 13 of whom were already on ceftriaxone and azithromycin.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Changes in antibiotic therapy among patients with positive Streptococcus urinary antigen tests.

Length of stay was significantly lower among patients with targeted antibiotic therapy (median 1.9, CI 1.5–5.7; p=0.016) compared with de-escalated antibiotics (4.5, CI 2.8–7). Inpatient mortality was significantly lower for patients with de-escalated antibiotic therapy (0%, n=0) compared with unchanged antibiotics (21%, n=8; p<0.001).

The BinaxNOW Streptococcus UAT costs $16.32 per the 2015 Medicare pricing from Centre for Medicare and Medicaid Services.

Discussion

Pneumococcal UAT had a meagre positive yield overall of 12% (134 out of 1110) in emergency department pneumonia patients admitted to the hospital, but significantly higher yield in intensive care unit patients. In the 20 patients that received targeted anti-pneumococcal therapy, there were only two positive blood cultures, making the positive UAT the only microbiological test in 18 patients to identify a causative organism. Physicians changed antibiotic management in the setting of a positive UAT in 72% of patients (combining targeted and de-escalated therapy together). Many of those without change in antibiotic were already receiving relatively narrow-spectrum ceftriaxone and azithromycin. The UAT is inexpensive; however, savings from de-escalating to targeted antibiotic therapy agents and experiencing fewer side effects from unnecessarily prolonged courses of broad-spectrum antibiotics may be substantial. While the yield is higher in intensive care unit patients, the low cost of UAT and the willingness of physicians who ordered the test to deescalate antibiotics based on its result suggest that it also has utility in patients admitted to ward settings. Our pessimistic hypothesis was therefore not confirmed by the findings of this study.

With the help of UAT, the pneumococcus was again the most commonly identified pathogen in patients admitted to the hospital with community-acquired pneumonia. The pneumococcus was identified in 52% of patients with an identified pathogen, 6% of the overall cohort of 2837. By comparison, recent studies of hospitalised patients with pneumonia have reported 21%, 17%, 15.9%, and 5% caused by the pneumococcus [15–18].

We found a low (one (5%) out of 20) relapse rate in those patients de-escalated to targeted therapy after positive UAT; even the one patient did not have relapse attributable to antibiotic de-escalation. Similarly, an observational study by Sorde et al. [6] showed that simplified therapy based on the urinary antigen test enabled directed therapy in 41 (8.6%) out of 474 of patients with community-acquired pneumonia without adverse effects. A prospective, randomised trial of 177 patients by Falguera et al. [7] showed that no difference in outcomes or adverse effects with targeted parenteral antibiotic therapy, although three (12%) out of 25 patients changed to oral amoxicillin did relapse versus three (2%) out of 150 other patients; p=0.04). A recent multicentre Spanish study reported a 23% yield of the UAT among 3865 pneumonia patients where 30 day mortality (6%) and the rate of intensive care unit admission (7%) were lower than in our study [10]. The pneumococcus comprised 21% of the pathogens. Molinos et al. [15] derived predictors for a positive test, mostly factors associated with higher severity of illness. A similar analysis in our study resulted in the best prediction simply being intensive care unit admission.

Patients with risk factors for HCAP were less likely to be tested, and had a lower rate of positive UAT results. However, the positive yield of UAT again documents the presence of usual, non-resistant pathogens among HCAP patients. As HCAP does not accurately select patients with resistant pathogens, and broad-spectrum antibiotic therapy does not improve their outcome, we do not recommend considering HCAP factors in the decision to order pneumocococcal UAT [19]. The HCAP concept was never adopted in Europe, and is “mostly dead” in North America.

Limitations

Our results may not be generalisable to other patient populations and hospitals since all seven hospitals are part of the same healthcare system located in a single geographic region. In addition, this is a secondary analysis of patients identified by ICD-9 coding and radiographic evidence of pneumonia. However, we previously reported that our case definition had a sensitivity of 0.68 and specificity of 0.99 compared with pneumonia diagnosis by physician case review [10]. Finally, this study is based on a “real world”, observational database where the decision of a physician to order UAT testing and act on its results were not influenced by the study team.

This study supports the use of pneumocococcal UAT testing as an inexpensive, noninvasive test that favourably influenced antibiotic prescribing. With increasing concern regarding antibiotic stewardship, the ability to safely and quickly narrow antibiotic therapy is increasingly important. Combined with clinical judgment demonstrated in this “real world” study, we encourage physicians to target antibiotic therapy towards Streptococcus pneumonia even if the UAT is the only positive microbiologic test.

Acknowledgement

This work was presented as an abstract at the American Thoracic Society International Conference 2015, Denver, CO, USA.

Footnotes

  • Support statement: This study was supported by the Intermountain Research and Medical Foundation, Salt Lake City, UT, USA. Funding information for this article has been deposited with the Open Funder Registry.

  • Conflict of interest: None declared.

  • Received January 29, 2016.
  • Accepted August 12, 2016.
  • Copyright ©ERS 2016

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A, et al.
    Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44: S27–S72.
    OpenUrlFREE Full Text
  2. ↵
    1. Bartlett JG
    . Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52: Suppl. 4, S296–S304.
    OpenUrl
  3. ↵
    1. Blaschke AJ
    . Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis 2011; 52: Suppl. 4, S331–S337.
    OpenUrl
  4. ↵
    1. Zalacain R,
    2. Capelastegui A,
    3. Ruiz LA, et al.
    Streptococcus pneumoniae antigen in urine: Diagnostic usefulness and impact on outcome of bacteraemic pneumococcal pneumonia in a large series of adult patients. J Asian Pac Soc Respirology 2014; 19: 936–943.
    OpenUrl
  5. ↵
    1. Sinclair A,
    2. Xie X,
    3. Teltscher M, et al.
    Systematic Review and Meta-Analysis of a Urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 51: 2303–2310.
  6. ↵
    1. Sorde R,
    2. Falco V,
    3. Lowak M, et al.
    Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171: 166–172.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Falguera M,
    2. Ruiz-González A,
    3. Schoenenberger JA, et al.
    Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. Thorax 2010; 65: 101–106.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. van der Eerden MM,
    2. Vlaspolder F,
    3. de Graaff CS, et al.
    Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672–678.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Lim WS,
    2. Baudouin SV,
    3. George RC, et al.
    BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. III, iii1–iii55.
    OpenUrlFREE Full Text
  10. ↵
    1. Dean NC,
    2. Jones BE,
    3. Jones JP, et al.
    Impact of an Electronic Clinical decision support tool for emergency department patients with pneumonia. Ann Emerg Med 2015; 66: 511–520.
    OpenUrlCrossRefPubMed
  11. ↵
    1. McCauley LM,
    2. Webb BJ,
    3. Sorensen JS, et al.
    Use of tracheal aspirate culture in newly intubated patients with community-onset pneumonia. Ann Am Thorac Soc 2016; 13: 376–381.
    OpenUrlPubMed
  12. ↵
    American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416.
    OpenUrlCrossRefPubMed
    1. Jones J,
    2. Bewick T,
    3. Lim WS, et al.
    CURB-65 pneumonia severity assessment adapted for electronic decision support. Chest 2011; 140: 156–163.
    OpenUrlCrossRefPubMed
    1. Jones BE,
    2. Jones JP,
    3. Vines CG, et al.
    Validating hospital admission criteria for decision support in pneumonia. BMC Pulm Med 2014; 14: 149.
    OpenUrlPubMed
  13. ↵
    1. Molinos L,
    2. Zalacain R,
    3. Menendez R, et al.
    Sensitivity, specificity, and positivity predictors of the pneumococcal urinary antigen test in community-acquired pneumonia. Ann Am Thorac Soc 2015; 12: 1482–1489.
    OpenUrlPubMed
    1. Musher DM,
    2. Roig IL,
    3. Cazares G, et al.
    Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67: 11–18.
    OpenUrlCrossRefPubMed
    1. Postma DF,
    2. van Werkhoven CH,
    3. van Elden LJ, et al.
    Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372: 1312–1323.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Jain S,
    2. Self WH,
    3. Wunderink RG, et al.
    Community-acquired pneumonia requiring hospitalization. N Engl J Med 2015; 373: 2382.
    OpenUrlPubMed
  15. ↵
    1. Webb BJ,
    2. Dascomb K,
    3. Stenehjem E, et al.
    Predicting risk of drug resistant organisms in pneumonia: moving beyond the HCAP model. Respir Med 2015; 109: 1–10.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 2 Issue 4 Table of Contents
ERJ Open Research: 2 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals
Devin M. West, Lindsay M. McCauley, Jeffrey S. Sorensen, Al R. Jephson, Nathan C. Dean
ERJ Open Research Oct 2016, 2 (4) 00011-2016; DOI: 10.1183/23120541.00011-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals
Devin M. West, Lindsay M. McCauley, Jeffrey S. Sorensen, Al R. Jephson, Nathan C. Dean
ERJ Open Research Oct 2016, 2 (4) 00011-2016; DOI: 10.1183/23120541.00011-2016
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endobronchial autologous BM-MSCs in IPF patients
  • Effect of β-blockers on the risk of COPD exacerbations
  • Recurrence of symptoms after childhood LRTI
Show more Original articles

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society